CIK 0001130598 · Non-accelerated filer<br>Smaller reporting company
Traws Pharma, Inc.
Sign in to watch- Ticker
- TRAW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 267-759-3680
- Business address
- 12 PENNS TRAIL, NEWTOWN, PA, 18940
- Former names
- Onconova Therapeutics, Inc., ONCONOVA THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-09 | Pauza Charles David Chief Science Officer Virology | Grant or award · Stock Option (right to buy) | +97,000 | 97,000 | ||
| 2026-07-09 | Savchuk Nikolay Chief Operating Officer | Grant or award · Stock Option (right to buy) | +93,000 | 93,000 | ||
| 2026-07-09 | CAUTREELS WERNER Director | Grant or award · Stock Option (right to buy) | +14,150 | 14,150 | ||
| 2026-07-09 | Parker Charles Nolan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2026-07-09 | Redfield Robert Chief Medical Officer | Grant or award · Stock Option (right to buy) | +84,000 | 84,000 | ||
| 2026-07-09 | Clarke Trafford Director | Grant or award · Stock Option (right to buy) | +14,150 | 14,150 | ||
| 2026-07-09 | Shoemaker Mary Teresa Director | Grant or award · Stock Option (right to buy) | +14,150 | 14,150 | ||
| 2026-07-09 | Dukes Iain D. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +274,000 | 274,000 | ||
| 2026-07-09 | Leaman John Harold Director | Grant or award · Stock Option (right to buy) | +14,150 | 14,150 | ||
| 2026-07-09 | STOVER JACK E Director | Grant or award · Stock Option (right to buy) | +14,150 | 14,150 | ||
| 2026-04-16 | ORBIMED ADVISORS LLC 10% owner | Purchase | +597,729 | $1.67 | $998K | 1,203,250 |
| 2026-04-16 | ORBIMED ADVISORS LLC 10% owner | Purchase · Series A Warrants (right to buy) | +597,729 | 597,729 | ||
| 2026-04-16 | ORBIMED ADVISORS LLC 10% owner | Purchase · Series B Warrants (right to buy) | +597,729 | 597,729 | ||
| 2026-04-16 | ORBIMED ADVISORS LLC 10% owner | Purchase · Series C Warrants (right to buy) | +1,793,187 | 1,793,187 | ||
| 2026-03-08 | Parker Charles Nolan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +104,544 | 104,544 | ||
| 2026-03-08 | Redfield Robert Chief Medical Officer | Grant or award · Stock Option (right to buy) | +108,854 | 108,854 | ||
| 2026-03-08 | Pauza Charles David Chief Science Officer Virology | Grant or award · Stock Option (right to buy) | +118,367 | 118,367 | ||
| 2026-03-08 | Savchuk Nikolay Chief Operating Officer | Grant or award · Stock Option (right to buy) | +96,899 | 96,899 | ||
| 2026-03-08 | Clarke Trafford Director | Grant or award · Stock Option (right to buy) | +33,435 | 33,435 | ||
| 2026-03-08 | Shoemaker Mary Teresa Director | Grant or award · Stock Option (right to buy) | +33,435 | 33,435 |
Page 1 of 9 · 170 trades